Ronald Kelley, MD
Psychiatry · Paducah, KYNPI 1033196019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 30.7% of the total. Reporting peaked in 2023 at $673 and has fallen 97.2% since, to $19 in 2025.
Across 125 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$791
- Sunovion Pharmaceuticals Inc.$458
- AbbVie$280
- Neurocrine Biosciences, Inc.$230
- Johnson & Johnson$224
- Takeda Pharmaceuticals U.S.A., Inc.$154
- plus $437 from 11 others
What the payments were for
- Food & beverage$2,47896%
- Education$964%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $791 |
| Sunovion Pharmaceuticals Inc. | 26 | $458 |
| AbbVie(2 entities) | 12 | $280 |
| Neurocrine Biosciences, Inc. | 3 | $230 |
| Johnson & Johnson | 12 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $154 |
| Corium, LLC | 4 | $93 |
| Jazz Pharmaceuticals Inc. | 4 | $82 |
| Shire North American Group Inc | 3 | $57 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Gilead | 2 | $37 |
| Indivior Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Pear Therapeutics (US), Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,573 in reported general payments places this provider in the 80th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $1,721 |
| Aripiprazole | 23 | $1,521 |
| Vilazodone Hcl | 17 | $1,442 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $1,115 |
| Oxcarbazepine | 13 | $974 |
| Buspirone Hcl | 53 | $865 |
| Gabapentin | 68 | $850 |
| Lurasidone Hcl | 11 | $792 |
| Trazodone Hcl | 44 | $758 |
| Liothyronine Sodium | 20 | $581 |
| Propranolol Hcl | 32 | $551 |
| Duloxetine Hcl | 35 | $547 |
| Clonazepam | 75 | $500 |
| Buprenorphine Hcl | 12 | $481 |
| Alprazolam | 107 | $457 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Paducah
- David MeyerPaducah$17K
- Laurie BallewPaducah$3K
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.